In the US, Saxagliptin (saxagliptin systemic) is a member of the drug class dipeptidyl peptidase 4 inhibitors and is used to treat Diabetes, Type 2.
US matches:
- Saxagliptin
- Saxagliptin/Metformin Extended-Release Tablets
- Saxagliptin and metformin
- Saxagliptin/Metformin Hydrochloride
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
A10BH03
CAS registry number (Chemical Abstracts Service)
0361442-04-8
Chemical Formula
C18-H25-N3-O2
Molecular Weight
315
Therapeutic Category
Oral antidiabetic agent, dipeptidyl peptidase-4 (DPP-4) inhibitor, gliptin
Chemical Names
(1S,3S,5S)-2-[(2S)-Amino(3-hydroxytricyclo[3.3.1.1³,⁷]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]-hexane-3-carbonitrile (USAN)
(1S,3S,5S)-2-{(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile (WHO)
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3.1.1³,⁷]dec-1-yl)acetyl]-, (1S,3S,5S)- (USAN)
Foreign Names
- Saxagliptinum (Latin)
- Saxagliptin (German)
- Saxagliptine (French)
- Saxagliptina (Spanish)
Generic Names
- Saxagliptin (OS: USAN)
- BMS 477118 (IS)
- OPC-262 (IS)
- UNII-8I7IO46IVQ (IS)
- UNII-Z8J84YIX6L (IS)
Brand Names
- Onglyza
AstraZeneca, Belgium; AstraZeneca, Switzerland; AstraZeneca, United Kingdom; Bristol-Myers Squibb, United Kingdom; Bristol-Myers Squibb, Greece; Bristol-Myers Squibb, Sweden; Bristol-Myers Squibb, United States; Bristol-Myers Squibb/AstraZeneca, Germany
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
